Representative publications

Value, economics, and equity

MacDonald K, et al. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal cancer. Journal of Medical Economics 2024;27(Suppl.3):1-8.

Altawalbeh SM, et al. Cost-effectiveness of intravenous resuscitation fluids in sepsis patients: a patient-level data analysis in Jordan. Journal of Medical Economics 2024;27:126-133.

Halloush S, et al. Economic evaluation of three BRAF+MEK inhibitors for the treatment of advanced unresectable melanoma with BRAF mutation from a US payer perspective. Annals of Pharmacotherapy 2023;57:1016-1024.

Oh M, et al. Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert Review of Pharmacoeconomics and Outcomes Research 2023;23:297-308.

Oh M, et al. Economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Review of Pharmacoeconomics and Outcomes Research 2023;23:309-316.

Oh M, et al. Economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Pharmacoeconomics and Outcomes Research 2023;23:317-325.

Alrawashdh N, et al. Cost-effectiveness and economic burden analyses of all first-line treatments of chronic lymphocytic leukemia. Value in Health 2022;25:1685-1695.

Obeng-Kusi M, et al. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis. Journal of Medical Economics 2022;25:894-902.

Abraham I, et al. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer in the United States. Journal of Managed Care and Specialty Pharmacy 2022;28:435-448.

Alrawashdh N, et al. Cost-effectiveness and value of information analyses of bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States. Journal of Managed Care and Specialty Pharmacy 2022;28:390-400.

Abraham I, et al. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of Medical Economics 2021;24(Suppl 1):71-83.

Obeng-Kusi M, et al. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. Journal of Medical Economics 2021;24(Suppl 1):1-13.

Calamia M, et al. Economic evaluation of polatuzumab-bendamustine-rituximab vs tafasitamab-lenalidomide in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma using classical and novel metrics. Journal of Medical Economics 2021;24(Suppl 1):14-24.

Choi BM, et al. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of Medical Economics 2021;24(Suppl 1):34-41.

McBride A, et al. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of Medical Economics 2021;24:743-756.

Alkhatib N, et al. Ex ante economic evaluation of Arg389 genetically targeted treatment with bucindolol versus empirical treatment with carvedilol in NYHA III/IV heart failure. American Journal of Cardiovascular Drugs 2021;21:205-217.

Alkhatib NS, Abraham I. The Six Delta platform for outcome-based pricing of pharmaceuticals. Journal of Medical Economics 2020;23:1209-1214. (lead article of a set of 8 articles describing the six dimensions and their aggregate)

Oh M, et al. Cost analysis of adjunctive hydrocortisone therapy for septic shock: US payer perspective. Critical Care Medicine 2020;48:e906-e911.

Almutairi AR, et al. Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy versus ipilimumab in patients with advanced unresectable melanoma. JAMA Dermatology 2019;155:22-28.

Kelley EF, et al. Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. Journal of Medical Economics 2018;21:1246-1253.

Gharaibeh M, et al. Economic evaluation for the UK of systemic chemotherapies in first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics 2018;36:1333-1343.

Alkhatib N, et al. Economic evaluation of genetic testing for Arg389 in the management of stage III/IV heart failure. Expert Review of Precision Medicine and Drug Development 2018;3:319-329.

Gharaibeh M, et al. Economic evaluation for USA of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics 2018;36:1273-1284.

Aljabri A, et al. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood 2016;128:3043-3051.

Sun D, et al. Emergency department visits in the United States for pediatric depression: estimates of charges and hospitalization. Academic Emergency Medicine 2014;21:1003–1014.

Abraham I, et al. The cost of blood transfusion in Western Europe as estimated from six studies. Transfusion 2012;52:1983-1988.

Rothberg M, et al. Improving nurse to patient staffing ratios as a cost-effective safety intervention. Medical Care 2005;48:785-791.

Disclosure: The publications listed here blend articles reporting on studies and projects contracted to MATRIX45 and predecessor companies, independent projects initiated by MATRIX45, as well as academic projects by Ivo Abraham’s research group at the University of Arizona.